Early-Stage Healthcare Venture Capital
Founded by practitioners averaging over a decade of frontline biotech investment experience. We write the first institutional check across the full spectrum of healthcare innovation — from antibodies, ADCs, and cell & gene therapies, to brain-computer interfaces, neuromodulation, and AI-native health platforms.
Collaborate with usNew Divide Ventures is founded by practitioners averaging over a decade of hands-on biotech investment experience. We invest at the frontier of healthcare innovation — from novel therapeutics and AI-driven drug discovery, to brain-computer interfaces and AI-native health platforms — at seed to Series A, where scientific merit is highest and institutional access is lowest.
Our mandate spans the full spectrum: antibodies, ADCs (Antibody-Drug Conjugates), cell and gene therapies, and precision small molecules — alongside brain-computer interfaces, neuromodulation, and foundation models reshaping clinical workflows. We evaluate every opportunity from first principles — mechanism of action, translational evidence, regulatory path, and the depth of conviction in the founding team.
We are the institutional co-founder for founders with a genuinely differentiated insight. We provide the first capital, the strategic foundation, and long-term partnership to carry a program from concept to IND and beyond.
Stage
Pre-Seed — Series A
Focus
Pharma · Neurotech · AI×Health
Geography
HK · SH · SF
Each thesis driven by scientific conviction, not trend-following.
Next-generation biologics, ADCs, advanced therapies, and targeted small molecules addressing validated mechanisms with unmet clinical need.
AI/ML-driven target identification and high-throughput screening that compresses discovery from years to months.
Brain-computer interfaces, neuromodulation, and next-generation neurotechnology platforms redefining how humans interact with, monitor, and restore their own biology.
Foundation models, multimodal clinical AI, and autonomous lab systems converging to compress the timeline from biological insight to clinical impact.
"We believe the next great medicines will come from founders the consensus has not yet recognized."
We respond to every serious founder. No warm introduction required — send your deck, a whitepaper, or a direct note.
Offices
Hong Kong
·Shanghai
·San Francisco